In Vivo CAR-T Takes the Stage at ASH 2026

A cluster of abstracts at ASH 2026 centers on in vivo CAR-T and in vivo gene-encoded T-cell engagers, approaches where cells or engagers are generated inside the patient rather than manufactured outside the body.

What’s on the program:

• Abstract 373 (Oral, 4:00–4:15 PM): “First-in-human clinical activity of an in vivo gene-encoded CD19×CD3 T-cell engager in relapsed/refractory B-cell malignancies: Interim results from sentry-CD19” (Short; NCT06533579). Session 613, Acute Lymphoblastic Leukemias.
• Abstract 280 (Oral, 2:45–3:00 PM): “T cell-specific delivery and genomic site-specific integration results in potent in vivo CAR T generation in models of hematological malignancies and non-human primates” (Tsuchida).
• Abstract 2350 (Poster): KSV01, an in vivo gene therapy generating anti-CD19 CAR-T cells in relapsed/refractory DLBCL (Zhu; NCT07260812).
• Abstract 2340 (Poster): IMV104, a CD19×CD20 dual-targeted in vivo CAR-T (Zhang).
• Abstract 2353 (Poster): Longitudinal single-cell RNA and TCR sequencing of lentivirus-based in vivo–generated CD19/BCMA CAR-T cells in multiple myeloma (Yan).

Why it matters for the clinical research community: trial teams will want to watch how these programs describe their dosing, monitoring and site requirements. OncologyCI will be following these sessions.